Aroa Biosurgery Ltd (ASX: ARX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Aroa Biosurgery Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $360.67 million
P/E Ratio 31.65
Dividend Yield N/A
Shares Outstanding 341.86 million
Earnings per share 0.034
Dividend per share N/A
Year To Date Return -5.65%
Earnings Yield 3.16%
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Aroa Biosurgery Ltd (ASX: ARX)
Latest News

ARX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Aroa Biosurgery Ltd

Aroa Biosurgery Ltd is a soft tissue regeneration company. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company's principal market is the United States where it has five key products for sale targeting chronicwounds, hernia, plastics, and reconstructive surgery and trauma/limb salvage/tumor surgery.

ARX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
07 Dec 2021 $1.06 $-0.03 -2.76% 149,964 $1.07 $1.11 $1.01
06 Dec 2021 $1.09 $-0.03 -2.70% 258,972 $1.11 $1.12 $1.08
03 Dec 2021 $1.11 $-0.01 -0.89% 91,363 $1.13 $1.13 $1.11
02 Dec 2021 $1.12 $-0.02 -1.75% 813,673 $1.13 $1.14 $1.10
01 Dec 2021 $1.15 $0.01 0.88% 30,400 $1.16 $1.16 $1.13
30 Nov 2021 $1.14 $0.01 0.89% 133,556 $1.13 $1.17 $1.13
29 Nov 2021 $1.13 $-0.03 -2.59% 432,783 $1.13 $1.14 $1.12
26 Nov 2021 $1.16 $0.01 0.87% 244,252 $1.16 $1.18 $1.14
25 Nov 2021 $1.15 $0.00 0.00% 119,963 $1.15 $1.15 $1.15
24 Nov 2021 $1.15 $0.00 0.00% 204,316 $1.15 $1.15 $1.15
23 Nov 2021 $1.15 $0.01 0.88% 388,101 $1.15 $1.15 $1.14
22 Nov 2021 $1.14 $-0.01 -0.87% 143,911 $1.15 $1.15 $1.14
19 Nov 2021 $1.15 $0.00 0.00% 382,176 $1.15 $1.15 $1.14
18 Nov 2021 $1.15 $-0.01 -0.87% 88,479 $1.16 $1.16 $1.14
17 Nov 2021 $1.16 $0.02 1.76% 116,949 $1.14 $1.16 $1.14
16 Nov 2021 $1.14 $-0.02 -1.72% 97,082 $1.16 $1.16 $1.13
15 Nov 2021 $1.16 $0.06 5.45% 366,193 $1.09 $1.16 $1.09
12 Nov 2021 $1.10 $-0.01 -0.90% 76,802 $1.14 $1.14 $1.10
11 Nov 2021 $1.12 $-0.01 -0.89% 55,343 $1.14 $1.15 $1.10
10 Nov 2021 $1.12 $0.00 0.00% 143,727 $1.14 $1.14 $1.12
09 Nov 2021 $1.12 $0.00 0.00% 112,964 $1.12 $1.15 $1.11

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
19 Aug 2021 James (Jim) McLean Buy 102 $76,800
Exercise of options.
19 Aug 2021 James (Jim) McLean Exercise 102 $76,800
Exercise of options.
06 Aug 2021 Philip McCaw Transfer 2 $3,298,621
Off-market transfer. Deemed price
11 Jun 2021 Philip McCaw Buy 81 $61,443
Exercise of options.
11 Jun 2021 Philip McCaw Exercise 81 $61,443
Exercise of options.
22 Feb 2021 John Diddams Sell 200 $238,680
On-market trade.
09 Dec 2020 John Diddams Buy 165 $17,737
Exercise of options. As per announcement on 10/12/2020.
09 Dec 2020 John Diddams Exercise 165 $17,737
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr John Flower Diddams Non-Executive Director Nov 2019
Mr Diddams has over forty years' experience as a CFO, CEO and director of both private and publicly listed companies. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations' law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in a number of industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors. John is currently a non-executive director of New Zealand based Volpara Health Technologies Limited (ASX:VHT) and Surf Lakes Holdings Limited. He is also Chair of the Risk Committee of the company.
Mr Philip John McCaw Non-Executive Director Mar 2008
Mr McCaw is the Founding Partner of Movac, one of New Zealand's Venture Capital funds. Phil has over 20-years experience investing into New Zealand technology companies and helping to guide their growth. Phil was an early investor in Trade Me, New Zealand's on-line trading community, which was sold to Fairfax in 2006. He was also an early investor into PowerByProxi, a wireless power technology spin-out from Auckland University, which was sold to Apple in 2018. Outside of Movac, Phil remains an angel investor and maintains a personal angel investment portfolio. He is a advocate for the development of the entrepreneurial and early-stage investment eco-system in New Zealand and was the past Chair of the Angel Association of New Zealand; a founding investor in the Lightning Lab technology accelerator; and a founding investor in the Kiwi Landing Pad in San Francisco. Prior to starting Movac Phil spent 10-years with Deloitte Consulting working in New Zealand and the USA.
Mr James (Jim) Neil McLean Non-Executive ChairmanNon-Executive Director Aug 2011
Mr McLean has gained 25 years experience serving as either Chair, Director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to Aroa, current appointments include Chair of Prevar Limited, R J Hill Laboratories Limited and Information Tools Limited. He was Chair of the New Zealand Institute of Plant & Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as deputy Chair. Jim was an executive and director of Genesis Research & Development Corporation Limited during its early stages through public listing. Before focusing in science and technology businesses, Jim held management positions with an international manufacturing business and spent thirteen years as a partner at chartered accountants, EY. His time at EY was focused on business strategy and included two years' secondment to EY's Washington DC office. He is a member of the Risk Committee.
Mr Steven (Steve) Barnard Engle Non-Executive Director Apr 2015
Mr Engle has over 20 years of executive leadership experience with public biotech companies developing products in metabolic, autoimmune, oncologic and infectious disease areas. He is the Chief Executive Officer of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Before joining CohBar, Steven served as CEO of Averigon Consulting, an advisory firm to the life science industry, supporting companies through product partnering, regulatory planning, investor relations and executive management. Previously, he was Chairman and CEO of XOMA Corporation, a leader in the development of therapeutic antibodies and antibody technologies. Prior to XOMA, Steven served as Chairman and CEO of La Jolla Pharmaceutical Company. Earlier, he served as Vice President of Marketing for Cygnus, a drug delivery systems company, where he helped to gain FDA approval and to launch Nicotrol for smoking cessation. Steven is the non-executive Chairman of the Board of Prescient Therapeutics Ltd., an ASX listed clinical stage oncology company, and a director of the board of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM, and was a Member of the board of the Lupus Foundation of America.
Mr John Richard Pinion II Non-Executive Director Feb 2015
Mr Pinion has over 26 years of experience in biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical Development and QC. In the ten years prior to joining Ultragenyx, John has held roles of increasing responsibility at Genentech (subsequently Roche post Genentech acquisition), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland. Previous to Genentech, John spent 17 years in operational and senior leadership roles in Baxter International's Renal, Bioscience, Parenterals and Device divisions. He is also member of the Risk Committee of the company.
Mr Brian Roderick Ward Chief Executive OfficerManaging Director Sep 2007
Mr Ward has held senior corporate roles in life sciences and health care companies over the last 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on a number of government and industry expert panels.
Ms Tracy Weimar Joint Company Secretary Jul 2020
Mr James Blair Agnew Chief Financial OfficerJoint Company Secretary
James Blair Agnew Chief Financial OfficerJoint Company Secretary
Tracy Weimar Joint Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mark Ritcher (Ritcher Investments A/C) 200,890,889 1.37%
Mr Brian Ward & Mrs Tracey Ward (Arawai No 2 A/C) 33,125,800 11.02%
Movac Fund 3 Lp 18,679,050 6.21%
Citicorp Nominees Pty Limited 17,856,411 5.94%
Phil Mccaw (Mcsyth Capital Investment A/C) 16,722,425 5.56%
National Nominees Limited 16,075,659 5.35%
J P Morgan Nominees Australia Pty Limited 13,774,374 4.58%
Richard Abbott (Jester 002 Investment A/C) 11,579,775 3.85%
Hsbc Custody Nominees (Australia) Limited 8,293,333 2.76%
Washington H Soul Pattinson And Company Limited 7,499,800 2.49%
Aspire Nz Seed Fund Ltd 7,491,000 2.49%
Sparkbox Investments Ltd 7,312,050 2.43%
K One W One (No 3) Ltd 5,882,550 1.96%
Bnp Paribas Nominees Pty Ltd (Agency Lending Drp A/C) 5,051,704 1.68%
Bnp Paribas Noms Pty Ltd (Drp) 4,835,542 1.61%
Bnp Paribas Noms Pty Ltd (Drp) I 4,819,950 1.60%
Sharon Bryant (Ot Investment A/C) 4,815,198 1.60%
Mesynthes Nominees Ltd20 4,580,250 1.52%
Custodial Services Limited (Beneficiaries Holding A/C) 4,120,200 1.37%
Nancy Yopp 3,913,842 1.30%